Re: Financials

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Financials

in response to

Re: Financials

KOO-KOO2

posted on Aug 09, 2019 11:05AM

"Last year it reported quarterly. It is not following suit this year."

For the past few years, the MD&A has been filed on SEDAR mid- to late-month in March, August, September and December. Not sure why they file in this pattern, but so far this year's pattern is no different than the past few years. If the pattern continues, next MD&A will be mid- to late- August 2019.